Table 2.

Characteristics of patients with HCV with 2-year mortality compared with those without after undergoing primary elective TJA

Variable	Mortality (n = 16)	No mortality (n = 153)	p value
Viral load positive	44 (7)	61 (93)	0.20
Viral load, IU/mL	0.8x106 ± 2.3x106	1.7x106 ± 3.6x106	0.16
HCV QL10, LogIU/mLa	2.6 ± 3.0	3.6 ± 3.0	0.17
Genotype
1a	31 (5)	48 (74)	0.30
1b	13 (2)	12 (18)
2b	25 (4)	14 (21)
3a	6 (1)	5 (8)
4	6 (1)	5 (8)
Indeterminate	19 (3)	16 (24)
Treatment group
Untreated	44 (7)	59 (91)	0.68
Interferon	44 (7)	21 (32)
Direct-acting antivirals	13 (2)	20 (30)
Failed viral therapy	13 (2)	12 (19)	> 0.99
Time from 0 VL to surgery in months	83 ± 71	50 ± 45	0.08
Aspartate transaminase	47 ± 25	37 ± 36	0.02
Alanine transaminase	39 ± 20	39 ± 31	0.56
MELD levelb
1	75 (12)	82 (125)	0.95
2	25 (4)	12 (19)
3	0 (0)	6 (9)
Child-Pugh classc
A	56 (9)	97 (149)	< 0.001
B	38 (6)	3 (4)
C	6 (1)	0 (0)
Liver fibrosis staged
F0	0 (0)	17 (26)	0.046
F1	6 (1)	13 (20)
F2	6 (1)	9 (14)
F3	13 (2)	14 (21)
F4	44 (7)	17 (26)
Not obtained	31 (5)	30 (46)
Liver fibrosis activitye
A0	25 (4)	24 (36)	0.83
A1	38 (6)	31 (48)
A2	6 (1)	13 (20)
A3	0 (0)	2 (3)
Not obtained	31 (5)	30 (46)

Data presented as % (n) or mean ± SD.

^aQL10 = quantitative log 10.

^bMELD level: Level 1 (score 6 to 9), Level 2 (score 10 to 19), Level 3 (score 20 to 29).

^cChild-Pugh class: A (well compensated disease), B (significant liver function compromise), C (decompensated disease).

^dLiver fibrosis stage: F0: no fibrosis, F1: minimal fibrosis, F2: significant fibrosis, F3: severe fibrosis, F4: cirrhosis.

^eLiver fibrosis activity: A0: no activity, A1: mild activity, A2: moderate activity, A3: severe activity.